Esta página todavía está en inglés. Las páginas principales ya están en español.
Amendment H-8151 to HF 2551
Relating to price transparency for prescription drugs and cost-sharing calculations by carriers, and including applicability provisions
Never voted on
Filed March 11, 2020 in the House by
What it changes
AI summary This amendment requires drug manufacturers to report their total marketing and advertising costs in their annual reports. It also adds specific legal definitions for "interchangeable biological product" and "specialty drug" to be used in the bill.1
Read the amendment’s wording
- Page 3, after line 3 by inserting: “g. The aggregate manufacturer-level direct and administrative costs related to marketing and advertising of the prescription drug for the immediately preceding calendar year.”
- Page 7, after line 3 by inserting: “___. “Interchangeable biological product” means the same as defined in section 155A.3.”
- Page 7, after line 10 by inserting: “___. “Specialty drug” means the same as defined in section 510E.1.”
- Page 7, line 13, after “or” by inserting “need-based payments paid”
- Page 7, line 17, after “for” by inserting “a specialty drug or”
- Page 7, line 19, after “equivalent” by inserting “or an interchangeable biological product”
- Title page, by striking lines 1 through 3 and inserting “An Act relating to price transparency and cost-sharing for prescription drugs, and including applicability provisions.”
- By renumbering, redesignating, and correcting internal references as necessary.